← Back to Search

Magnetic Resonance Fingerprinting for Brain Cancer

N/A
Recruiting
Led By Chaitra A Badve, MD
Research Sponsored by Case Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of intra-axial brain tumor at initial diagnosis or patients with known treated brain tumors on follow-up with concern for imaging progression
Be older than 18 years old
Must not have
Known history of severe claustrophobia
Non-English speaking population
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new magnetic resonance fingerprinting technique to see if it can improve brain tumor diagnosis and assessment.

Who is the study for?
This trial is for adults with a new or previously treated brain tumor who can give informed consent themselves or through a legal representative. It's not for those with non-MRI safe implants, metallic foreign objects in their body, severe claustrophobia, pregnant women, prisoners, vulnerable populations, non-English speakers, or minors.
What is being tested?
The study tests Magnetic Resonance Fingerprinting (MRF), an advanced MR imaging technique that quickly scans and provides detailed tissue data. This will be compared to standard imaging and clinical information to check its accuracy in diagnosing and assessing brain tumors.
What are the potential side effects?
As MRF is a type of MRI scan without radiation exposure like X-rays or CT scans, it's generally considered safe. However, some may experience discomfort from the loud noises during scanning or anxiety due to being in a confined space.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a brain tumor that was either found at the start or has shown signs of growth on scans.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a severe fear of being in tight or enclosed spaces.
Select...
I do not speak English.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Treated tumors with possible recurrenceExperimental Treatment1 Intervention
Participants with treated brain tumors with possible recurrence will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be added to the repeat MRI studies as determined appropriate by the referring physician/primary care team.
Group II: Newly Diagnosed Brain TumorsExperimental Treatment1 Intervention
Participants with newly diagnosed brain tumors will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be performed to visualize recurrence.

Find a Location

Who is running the clinical trial?

Case Comprehensive Cancer CenterLead Sponsor
467 Previous Clinical Trials
32,571 Total Patients Enrolled
Chaitra A Badve, MDPrincipal InvestigatorUniversity Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center

Media Library

Magnetic Resonance Fingerprinting Clinical Trial Eligibility Overview. Trial Name: NCT02956291 — N/A
Brain Tumor Research Study Groups: Newly Diagnosed Brain Tumors, Treated tumors with possible recurrence
Brain Tumor Clinical Trial 2023: Magnetic Resonance Fingerprinting Highlights & Side Effects. Trial Name: NCT02956291 — N/A
Magnetic Resonance Fingerprinting 2023 Treatment Timeline for Medical Study. Trial Name: NCT02956291 — N/A
~0 spots leftby Dec 2024